Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 92.15% is in line with its 5-year average of 99.93%, near the high end of its 5-year range (-84.38%–100.00%).
54.01% above its 12-month average of 59.84%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
92.15%
GROSS MARGIN AVG TTM
59.84%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
99.93%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+54.01%
CURRENT VS 3Y AVG
-7.85%
CURRENT VS 5Y AVG
-7.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+122.69%
vs the sector median at left
NewAmsterdam Pharma Company N.V.
Market Cap
$2.52B
Gross Margin
92.15%
TTM Avg
59.84%
3Y Avg
100.00%
5Y Avg
99.93%
Market Cap
$2.57B
Gross Margin
7.61%
TTM Avg
10.03%
3Y Avg
9.93%
5Y Avg
9.40%
Market Cap
$2.45B
Gross Margin
88.07%
TTM Avg
88.93%
3Y Avg
87.75%
5Y Avg
88.00%
Market Cap
$2.61B
Gross Margin
84.05%
TTM Avg
-197.31%
3Y Avg
-176.53%
5Y Avg
-71811.06%
Market Cap
$2.41B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.40B
Gross Margin
18.57%
TTM Avg
22.55%
3Y Avg
18.71%
5Y Avg
13.63%
Market Cap
$2.66B
Gross Margin
46.93%
TTM Avg
47.02%
3Y Avg
48.36%
5Y Avg
47.58%
Market Cap
$2.66B
Gross Margin
31.95%
TTM Avg
33.09%
3Y Avg
31.97%
5Y Avg
31.83%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.52B | 92.15% | 59.84% | 100.00% | 99.93% |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | 7.61% | 10.03% | 9.93% | 9.40% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.45B | 88.07% | 88.93% | 87.75% | 88.00% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.61B | 84.05% | -197.31% | -176.53% | -71811.06% |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | 0.00% | 0.00% | 0.00% | 0.00% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | -61.96% | -19.42% | -14.39% | 23.74% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 18.57% | 22.55% | 18.71% | 13.63% |
| Neogen Corporation (NEOG)vs › | $2.66B | 46.93% | 47.02% | 48.36% | 47.58% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.66B | 31.95% | 33.09% | 31.97% | 31.83% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.65B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
92.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 83.55% |
| 2025-12-31 | -84.38% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 98.93% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
